CY1124821T1 - Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ - Google Patents

Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ

Info

Publication number
CY1124821T1
CY1124821T1 CY20211100929T CY211100929T CY1124821T1 CY 1124821 T1 CY1124821 T1 CY 1124821T1 CY 20211100929 T CY20211100929 T CY 20211100929T CY 211100929 T CY211100929 T CY 211100929T CY 1124821 T1 CY1124821 T1 CY 1124821T1
Authority
CY
Cyprus
Prior art keywords
igmesin
alzheimer
disease
treatment
disorders
Prior art date
Application number
CY20211100929T
Other languages
English (en)
Inventor
François J. ROMAN
Johann MEUNIER
Original Assignee
Sigmathera Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmathera Sas filed Critical Sigmathera Sas
Publication of CY1124821T1 publication Critical patent/CY1124821T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Η παρούσα εφεύρεσης αναφέρεται σε μεθόδους για θεραπεία νευροεκφυλιστικών ασθενειών και διαταραχών με ιγμεσίνη.
CY20211100929T 2016-02-11 2021-10-26 Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ CY1124821T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293832P 2016-02-11 2016-02-11
PCT/EP2017/053066 WO2017137600A1 (en) 2016-02-11 2017-02-10 Igmesine for use in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CY1124821T1 true CY1124821T1 (el) 2022-11-25

Family

ID=58009847

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100929T CY1124821T1 (el) 2016-02-11 2021-10-26 Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ

Country Status (17)

Country Link
US (1) US11129801B2 (el)
EP (2) EP3413870B1 (el)
JP (1) JP7059192B2 (el)
CN (1) CN109069414B (el)
AU (1) AU2017218592B2 (el)
CA (1) CA3012415C (el)
CY (1) CY1124821T1 (el)
DK (1) DK3413870T3 (el)
ES (1) ES2895957T3 (el)
HR (1) HRP20211661T1 (el)
HU (1) HUE056265T2 (el)
LT (1) LT3413870T (el)
PL (1) PL3413870T3 (el)
PT (1) PT3413870T (el)
RS (1) RS62615B1 (el)
SI (1) SI3413870T1 (el)
WO (1) WO2017137600A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3413870T (pt) 2016-02-11 2021-09-10 Sigmathera Sas Igmesina para utilização no tratamento de doença de alzheimer
AU2022346825A1 (en) * 2021-09-20 2024-03-07 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607824A (en) 1983-01-11 1986-08-26 Energy Absorption Systems, Inc. Guardrail end terminal
FR2636625B1 (fr) * 1988-09-01 1990-11-09 Jouveinal Sa Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
JP4600610B2 (ja) * 1996-05-15 2010-12-15 株式会社フジモト・コーポレーション アセチルコリン系神経伝達改善剤
AU2180400A (en) 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
EP1078630A1 (en) 1999-08-27 2001-02-28 Warner-Lambert Company Use of sigma receptor agonists for the treatment of depression
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002096415A2 (en) 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US20050070524A1 (en) 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
CN100420483C (zh) * 2003-06-12 2008-09-24 株式会社爱慕知科学 用于神经元再生和功能恢复的σ配体
CN1960781A (zh) 2004-04-14 2007-05-09 沃尼尔·朗伯有限责任公司 治疗阿尔茨海默氏病的治疗组合
US20070123556A1 (en) 2005-06-06 2007-05-31 University Of South Florida Treatment with Sigma Receptor Agonists Post-Stroke
FR2970869B1 (fr) * 2011-01-31 2013-09-06 Centre Nat Rech Scient Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
PT3413870T (pt) 2016-02-11 2021-09-10 Sigmathera Sas Igmesina para utilização no tratamento de doença de alzheimer

Also Published As

Publication number Publication date
PT3413870T (pt) 2021-09-10
CN109069414B (zh) 2022-01-14
PL3413870T3 (pl) 2022-01-10
CA3012415C (en) 2024-03-12
AU2017218592A1 (en) 2018-08-09
EP3413870A1 (en) 2018-12-19
JP2019504872A (ja) 2019-02-21
EP3413870B1 (en) 2021-08-04
EP3903767A1 (en) 2021-11-03
CA3012415A1 (en) 2017-08-17
HUE056265T2 (hu) 2022-02-28
LT3413870T (lt) 2021-11-10
US20190046472A1 (en) 2019-02-14
DK3413870T3 (da) 2021-11-01
AU2017218592B2 (en) 2022-10-20
JP7059192B2 (ja) 2022-04-25
WO2017137600A1 (en) 2017-08-17
CN109069414A (zh) 2018-12-21
RS62615B1 (sr) 2021-12-31
ES2895957T3 (es) 2022-02-23
HRP20211661T1 (hr) 2022-02-18
SI3413870T1 (sl) 2021-12-31
US11129801B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1124568T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης
CY1125436T1 (el) Αναστολεις dna-pk
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1124416T1 (el) Συνθεσεις ενωσεων και χρησεις αυτων
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1122981T1 (el) Συνθεσεις για διαμορφωση της εκφρασης του c9orf72
CY1120452T1 (el) Παραγωγο αμιδιου πυραζολης
CY1124563T1 (el) Βελτιωμενα antισωmata δεσμευσης πρωτοϊνιδιων α- βητα
CY1124704T1 (el) Παραγωγα sobetirome
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
CY1124767T1 (el) Rna για τη θεραπεια αυτοανοσων ασθενειων
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ
CY1124596T1 (el) Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση
EA201990400A1 (ru) Соединения и композиции и их применение
CY1124238T1 (el) Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης
CY1124699T1 (el) Ενωσεις
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
CY1123116T1 (el) Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα